dc.creator | Van Werkhoven, C. H. | es |
dc.creator | Ducher, A. | es |
dc.creator | Berkell, M. | es |
dc.creator | Mysara, M. | es |
dc.creator | Lammens, C. | es |
dc.creator | Torre-Cisneros, J. | es |
dc.creator | Rodríguez-Baño, Jesús | es |
dc.creator | Vehreschild, M. J. G. T. | es |
dc.date.accessioned | 2022-10-24T15:09:45Z | |
dc.date.available | 2022-10-24T15:09:45Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Van Werkhoven, C.H., Ducher, A., Berkell, M., Mysara, M., Lammens, C., Torre-Cisneros, J.,...,Vehreschild, M.J.G.T. (2021). Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics. Nature Communications, 12 (1), 2240. https://doi.org/10.1038/s41467-021-22269-y. | |
dc.identifier.issn | 2041-1723 | es |
dc.identifier.uri | https://hdl.handle.net/11441/138286 | |
dc.description.abstract | Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can
improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile
infection (CDI). Here, we report in a prospective observational cohort study the incidence of
CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007
patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta lactamase inhibitor, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolones or
clindamycin from 34 European hospitals. The estimated 90-day cumulative incidences of a
first CDI episode is 1.9% (95% CI 1.1-3.0). Carbapenem treatment (Hazard Ratio (95% CI):
5.3 (1.7-16.6)), toxigenic C. difficile rectal carriage (10.3 (3.2-33.1)), high intestinal abundance
of Enterococcus spp. relative to Ruminococcus spp. (5.4 (2.1-18.7)), and low Shannon alpha
diversity index as determined by 16 S rRNA gene profiling (9.7 (3.2-29.7)), but not nor malized urinary 3-indoxyl sulfate levels, predicts an increased CDI risk. | es |
dc.format | application/pdf | es |
dc.format.extent | 10 p. | es |
dc.language.iso | eng | es |
dc.publisher | Nature Publishing Group | es |
dc.relation.ispartof | Nature Communications, 12 (1), 2240. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.nature.com/articles/s41467-021-22269-y | es |
dc.identifier.doi | 10.1038/s41467-021-22269-y | es |
dc.contributor.group | Universidad de Sevilla. CTS-406: Estudio enfermedades infecciosas en la práctica clínica | es |
dc.journaltitle | Nature Communications | es |
dc.publication.volumen | 12 | es |
dc.publication.issue | 1 | es |
dc.publication.initialPage | 2240 | es |